Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지

EFFECTS OF ALENDRONATE AND PAMIDRONATE ON THE PROLIFERATION AND THE ALKALINE PHOSPHATASE ACTIVITY OF HUMAN BONE MARROW DERIVED MESENCHYMAL STEM CELLS

Alendronate와 Pamidronate가 인간 골수유래 간엽줄기세포의 증식과 알칼리성 인산분해효소 활성에 미치는 영향

  • Kim, Young-Ran (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental School) ;
  • Ryu, Dong-Mok (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental School) ;
  • Kwon, Yong-Dae (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental School) ;
  • Yun, Yong-Pil (Department of oral biology and institute of oral biology, Kyung Hee University Dental School)
  • 김영란 (경희대학교 치의학전문대학원 구강악안면외과학 교실) ;
  • 류동목 (경희대학교 치의학전문대학원 구강악안면외과학 교실) ;
  • 권용대 (경희대학교 치의학전문대학원 구강악안면외과학 교실) ;
  • 윤영필 (경희대학교 치의학전문대학원 구강생물학 교실)
  • Published : 2009.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study is to investigate the effects of alendronate and pamidronate on proliferation and the alkaline phosphatase activity of human bone marrow derived mesenchymal stem cells and to relate the results with bisphosphonate related osteonecrosis of the jaw(BRONJ). With the consent of patients with no systemic disease and undergoing iliac bone graft, cancellous bone was collected to obtain human bone marrow derived mesenchymal stem cells through cell culture. 96 well plate were prepared with a concentration of $10^4$cell/ well. Alendronate and pamidronate were added to each well with the concentration of $10^{-6}M$, $10^{-8}M$ and $10^{-10}M$, respectively. Then proliferation capacity of each well was evaluated with the cell counting kit. 24 well plates were prepared with a concentration of $10^5$cell/ml/well and with the bone supplement, alendronate and pamidronate were added with the concentration of $10^{-6}M$, $10^{-8}M$ and $10^{-10}M$, respectively on each plate. The plates were cultured for either 24 or 72 hours. Then the cells were sonicated to measure the alkaline phosphatase activity and protein assay was done to standardize the data for analysis. As the concentration of alendronate or pamidronate added to the culture increased, the proliferation capacity of the cells decreased. However, no statistical significance was found between the group with $10^{-10}M$ of bisphophonate and the control group. Pamidronate was not capable of increasing the alkaline phosphatase activity in all trials. However, alkaline phosphatase activity increased with 24 hours of $10^{-8}M$ of alendronate treatment and with 48 hours of $10^{-10}M$ of alendronate treatment. Cell toxicity increased as the bisphosphonate concentration increased. This seems to be associated with the long half life of bisphosphonate, resulting in high concentration of bisphosphonate in the jaw and thus displaying delayed healing after surgical procedures. Alendronate has shown to increase the alkaline phophatase activity of human bone marrow derived mesenchymal stem cells. However, this data is insufficient to conclude that alendronate facilitates the differentiation of human bone marrow derived mesenchymal stem cells. Further studies on DNA level and animal studies are required to support these results.

Keywords

References

  1. Heino TJ, Chagin AS, Takigawa M, Savendahl L. Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation. Bone 2008;42:702-9 https://doi.org/10.1016/j.bone.2008.01.001
  2. Devogelaer JP. New uses of bisphosphonates : osteohenesis imperfecta. Curr Opin Pharmacol 2002;2:748-3 https://doi.org/10.1016/S1471-4892(02)00218-7
  3. Kos M, Luczak K, Godzinski J, Klempous J. Treatment of monostotic fibrous dysplasia with pamidronate. J Craniomaxillofac Surg 2004;32:10-5 https://doi.org/10.1016/j.jcms.2003.07.009
  4. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 2004;34:747-54 https://doi.org/10.1016/j.bone.2003.12.011
  5. Cremers S, Sparidans R, den HJ, Hamdy N, Vermeij P, Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate(pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002;57:883-90 https://doi.org/10.1007/s00228-001-0411-8
  6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7 https://doi.org/10.1016/S0278-2391(03)00720-1
  7. Kwon YD, Yoon BW, Walter C. Bisphosphonate, is it an emerging risk factor in oral surgery? J Kor Assoc Maxillofac Plastic Recon Surg 2007;29:456-62
  8. Jung A, Bisaz, S, Fleisch H. The binding of pyrophosphate and two disphosphonates by hydroxyapatite crystals. Calcif. Tissue Res. 1973;11:269-80 https://doi.org/10.1007/BF02547227
  9. Marx RE. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaw : History, Etiology, Prevention, and treatment 1st ed. Canada: Quintessence., 2007
  10. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58 https://doi.org/10.2174/1381612033453640
  11. Cecchini MG, Felix R, Fleisch H, Cooper PH. Effect of bisphosphonates on proliferation and viability of mouse bone marrowderived macrophages. J Bone Miner Res 1987;2:135-42 https://doi.org/10.1002/jbmr.5650020209
  12. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-5 https://doi.org/10.1172/JCI114100
  13. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9 https://doi.org/10.1359/jbmr.1998.13.4.581
  14. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ et al. Alendronate mechanism of action : geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resoprtion and kinase activation in vitro. Proc Nati Acad Sci USA 1999;96:133-8 https://doi.org/10.1073/pnas.96.1.133
  15. van beek E, Lowik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suprression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999;14:722-9 https://doi.org/10.1359/jbmr.1999.14.5.722
  16. Reszka AA, Halasy-Nagy JM, Masarachia, PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst 1 kinase during apoptosis. J. Biol. Chem. 1999;274:34967-73 https://doi.org/10.1074/jbc.274.49.34967
  17. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-74 https://doi.org/10.1172/JCI6800
  18. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002;25:539-46 https://doi.org/10.1007/BF03345497
  19. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-15 https://doi.org/10.1016/j.biomaterials.2003.11.024
  20. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80 https://doi.org/10.1172/JCI119668
  21. Moreno GC, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML et al. Effect of alendronate on cultured normal human osteoblasts. Bone 1998;22:233-9 https://doi.org/10.1016/S8756-3282(97)00270-6
  22. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.Cancer Res 2000;60:6001-7
  23. Qiao C, Xu W, Zhu W, Hu J, Qian H, Yin Q et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int 2008;32:8-15 https://doi.org/10.1016/j.cellbi.2007.08.002
  24. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005;26:6941-9 https://doi.org/10.1016/j.biomaterials.2005.04.059
  25. Shani M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11 https://doi.org/10.1172/JCI116422
  26. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34 https://doi.org/10.1016/j.joms.2004.02.004
  27. Frank O, Heim M, Jakob M, Barbero A, Schafer D, Bendik I et al. Real-time quantitative RT-PCR analysis of human bone marrow stromal cells during osteogenic differentiation in vitro. J Cell Biochem 2002;85:737-46 https://doi.org/10.1002/jcb.10174
  28. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporosis International 1993;3:13-16 https://doi.org/10.1007/BF01623002